5-Fluorouracil, Cisplatin, Mitomycin, Vinorelbine Combination Chemotherapy

This regimen combines four distinct chemotherapeutic agents, each with its own mechanism of action: 1. **5-Fluorouracil (5-FU)**: A pyrimidine analog. 2. **Cisplatin**: A platinum-based compound. 3. **Mitomycin C**: An alkylating agent. 4. **Vinorelbine**: A vinca alkaloid. The combination leverages multiple mechanisms to attack cancer cells at different points in their life cycle, potentially offering synergistic effects. ## Clinical Applications This combination has been studied for use in several cancer types: - **Non-small cell lung cancer (NSCLC)**: Combinations of these agents (particularly vinorelbine, mitomycin C, and cisplatin) have shown efficacy. The specific study of mitomycin C, vinorelbine, and cisplatin (MNP) combination showed a high response rate of 51.7% in NSCLC patients. - **Head and neck squamous cell carcinoma**: Various combinations of these agents have been used in treating advanced, unresectable head and neck cancers. ## Administration - **5-FU**: Usually given as a continuous infusion over 4-5 days or continuously for 21 days. - **Cisplatin**: Administered as an intravenous infusion, often with hydration to protect the kidneys. - **Mitomycin C**: Given as an intravenous infusion, typically on day 1 of the treatment cycle. - **Vinorelbine**: Can be administered intravenously or orally as capsules. Treatment cycles are typically repeated every 3-4 weeks, with the exact schedule depending on the specific protocol and cancer type being treated. ## Side Effects Common side effects include: - Increased risk of infection due to neutropenia - Anemia and thrombocytopenia - Nausea and vomiting - Mucositis/stomatitis - Fatigue - Nephrotoxicity (from cisplatin) - Neurotoxicity - Electrolyte imbalances